No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantation†
Article first published online: 18 APR 2007
Copyright © 2007 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 96, Issue 1, pages 62–68, 1 July 2007
How to Cite
Wu, L., Xu, X., Shen, J., Xie, H., Yu, S., Liang, T., Wang, W., Shen, Y., Zhang, M. and Zheng, S. (2007), MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantation. J. Surg. Oncol., 96: 62–68. doi: 10.1002/jso.20774
- Issue published online: 13 JUN 2007
- Article first published online: 18 APR 2007
- Manuscript Accepted: 4 JAN 2007
- Manuscript Received: 5 OCT 2006
- multidrug resistance 1 gene;
- single nucleotide polymorphism;
- multivariate analysis;
- molecular marker
Background and Objectives
Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) remains a major cause of post-LT death. However, currently there is still lacking the markers to reliably predict recurrence. This study was undertaken to evaluate the association between three polymorphisms (C1236T, G2677A/T, C3435T) of Multidrug resistance 1 (MDR1) gene and the risk of recurrence after LT.
Genomic DNA of 99 HCC patients undergoing LT was extracted from peripheral blood lymphocytes and genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism assay. Cox proportional hazard model was used to estimate the hazard ratios associated with polymorphisms.
During a mean follow-up of 14.9 months, 49 patients experienced recurrence. The association between recurrence-free and 2677A carrier (carrying at least one variant A allele) was significant (P = 0.019). However, no significant association was observed in other polymorphisms. Patients with 2677A carrier conferred a 63% reduction in recurrence risk compared with 2677A non-carrier (odds ratio: 0.374; 95% confidence interval: 0.177–0.788; P = 0.010). The median recurrence-free survival for 2677A carrier group was significantly longer than that for 2677A non-carrier group (44.2 vs. 10.5 months, P = 0.015).
The polymorphism of MDR1 gene may be a valuable molecular marker for HCC recurrence after LT. J. Surg. Oncol. 2007;96:62–68. © 2007 Wiley-Liss, Inc.